Myasthenia Gravis

Two genes were shown to be significantly associated with higher prevalence of myasthenia gravis (MG), a relatively rare autoimmune disease.

Researchers identify certain predictive factors that impact the prognosis of patients with myasthenia gravis and COVID-19 infection.

Thoracoscopic thymectomy yielded quicker recovery time in myasthenia gravis (MG) while reducing disease severity, the need for treatment, and complications.

The researchers have detailed their complete findings of subcutaneous (SC) vs intravenous (IV) efgartigimod in generalized myasthenia gravis (gMG) from the phase 3 ADAPT-SC trial and initial findings from the open-label extension of the study, ADAPT-SC+.

A study suggests most patients with myasthenia gravis (MG) can take statins without experiencing symptom worsening.

New research shows how repetitive nerve stimulation and single fiber electromyography can help diagnose disorders such as myasthenia gravis.

The potential value of these biomarkers may help differentiate acetylcholine receptor antibody seropositive (AChR+) myasthenia gravis (MG) from healthy patients.

If integrated into clinical practice, the approach could fill a need for more optimal diagnostic approaches for myasthenia gravis (MG), explained the researchers.

A survey of patients with myasthenia gravis in 5 European countries suggests patients wait on average about a year after symptom onset before they are given an accurate diagnosis.

A single-center cohort study found no differences between males and females in the odds of starting or time to treatment in generalized myasthenia gravis (gMG), but investigators want to continue to probe more deeply into why women are more severely affected by the disease.

The decremental response follows repetitive nerve stimulation (RNS) completed earlier in proximal muscles compared with distal muscles in a study of patients with myasthenia gravis (MG) and amyotrophic lateral sclerosis (ALS).

A series of portable respiratory function tests for patients with mild to moderate myasthenia gravis (MG) were found to be useful methods to diagnose previously unidentified at-risk cases for respiratory deterioration.

A recent case report highlights the fatal risks of pembrolizumab, an immune checkpoint inhibitor, after an 87-year-old patient developed severe immune-related adverse events.

The analysis represents an effort to use bioinformatics to find potential new therapeutic targets for myasthenia gravis (MG).

A recent study showed that the Myasthenia Gravis (MG) Symptoms PRO scales viably measure core symptoms of the disease.

A new report offers safety and efficacy data on a population with generalized myasthenia gravis (gMG) not represented in the drug’s pivotal phase 3 trial.

A new case report details the successful use of efgartigimod as a rescue medication in a patient with therapy-refractory myasthenic crisis.

A new study has found that myasthenia gravis does not affect the long-term prognosis of patients with thymoma.

Patients with myasthenia gravis who received treatment within a year from diagnosis were generally in accordance with guideline suggestions.

More than 60% of complement inhibitor–naive patients with acetylcholine receptor–positive generalized myasthenia gravis (MG) in diverse clinical populations had a clinically meaningful reduction in MG activities of daily living scores.

A 43-year-old woman had 2 myasthenic crises within 3 months, with both taking place shortly after exposure to hair dye containing methylisothiazolinone (MIT).

Results of a recent database analysis reveal that patients with juvenile myasthenia gravis—particularly prepubescent girls—might benefit from early thymectomy to cut production of autoreactive AChR B cells. Usually, though, it’s not done.

Study findings show eculizumab is effective and well tolerated in reducing disease burden in adolescents with refractory anti-acetylcholine receptor antibody–positive generalized myasthenia gravis.

There currently are no guidelines on how to treat this patient group, despite a high risk of mortality.

Although further research is needed, these new findings suggest that using the 2 intranasal sprays is an effective option for patients with myasthenia gravis (MG) who experience eyelid drooping.